--> +1.8% Pre-Mkt - very low volume
Reports Q4 (Dec) earnings of $1.26 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus Estimate of $1.25; revenues rose 16.4% year/year to $4.37 bln vs the $4.25 bln consensus.
Co issues guidance for Q1, sees EPS of $1.06-1.09, excluding non-recurring items, vs. $1.14 Capital IQ Consensus Estimate; sees Q1 revs of +13-14% ex F/X calc to ~$3.90-3.93 bln, may not be comparable to $3.98 bln Capital IQ Consensus Estimate.
Co issues guidance for FY14, sees EPS of $5.05-5.25, excluding non-recurring items, vs. $5.01 Capital IQ Consensus Estimate; sees FY14 revs of +9-10% ex F/X to ~$16.63-16.78 bn, may not be comparable to $16.69 bln Capital IQ Consensus Estimate.
Worldwide sales totaled $4.4 billion and increased 16 percent from prior-year levels. Excluding the contribution of Gambro revenues in the quarter, Baxter's sales increased 5 percent to $4.0 billion (or 6 percent excluding the impact of foreign currency). Sales within the United States totaled $1.8 billion and advanced 13 percent, and international sales of $2.6 billion increased 19 percent (or 20 percent excluding the impact of foreign currency).